Streetbeat News

Regulatory

ALTR

Trading for ALTR was halted at 4:27:00 p.m. ET due to pending news. This indicates that significant information regarding the company is expected to be released soon, which could impact its stock price.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 8:27 pm

HIMS

NVO

Hims & Hers Health Inc. (NYSE:HIMS) shares fell after the FDA announced the availability of Novo Nordisk's (NYSE:NVO) drugs Ozempic and Wegovy, which may end the demand for compounded versions that Hims & Hers benefited from.

Portfolio Pulse from Vaishali Prayag

October 30, 2024 | 8:20 pm

HOOD

Robinhood has announced its expected GAAP total operating expenses for fiscal year 2024 to be between $1.86 billion and $1.96 billion. This includes a $10 million regulatory accrual in the third quarter of 2024.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 8:13 pm

IVA

Inventiva announced that the Data Monitoring Committee has recommended the continuation of their clinical trial without any modifications to the current protocol, following a pre-planned review of safety data.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 8:05 pm

IVA

Inventiva's NATiV3 Phase 3 clinical trial for lanifibranor in MASH patients continues as planned, following a positive safety review by the Data Monitoring Committee.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 8:01 pm

MCD

SPY

The CDC reports an E. Coli O157:H7 outbreak affecting 90 people across 13 U.S. states as of October 30. This could impact companies in the food industry, such as McDonald's, and broader market indices like SPY.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 7:45 pm

TCNNF

Florida Governor Ron DeSantis is intensifying his campaign against two proposed amendments to the Florida Constitution concerning recreational marijuana legalization and abortion rights. Despite significant public support for both amendments, DeSantis is using state funds for advertising to oppose them. Trulieve Cannabis Corp. is involved in the campaign for marijuana legalization.

Portfolio Pulse from Maureen Meehan

October 30, 2024 | 7:28 pm

HIMS

Hims & Hers Health shares are experiencing a decline, potentially due to the FDA listing Ozempic and Wegovy as available medications.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 7:19 pm

BSX

EW

MDT

Boston Scientific's ACURATE IDE trial results for the ACURATE neo2 Aortic Valve System did not meet the non-inferiority criteria compared to control valves, leading to a 1.66% drop in BSX stock. The trial's results were presented at a major cardiovascular symposium.

Portfolio Pulse from Vandana Singh

October 30, 2024 | 7:08 pm

NVO

Novo Nordisk's diabetes and obesity drugs, Ozempic and Wegovy, are now listed as available by the FDA, potentially ending their shortage status. This could impact compounding pharmacies and patients who rely on compounded versions of these drugs.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 6:52 pm